S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00003587
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of two different combination chemotherapy regimens in treating patients who have stage IIIB or stage IV non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +6 locations
Conditions: Lung Cancer
Register for Updates
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
NCT00373256
Completed
To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2012
Locations: Pfizer Investigational Site, Amarillo, Texas +28 locations
Conditions: Breast Neoplasms
Register for Updates
S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
NCT00100789
Completed
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine together with paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with paclitaxel works in treating patients with persistent, recurrent, or metastatic head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2012
Locations: Medical City Dallas Hospital, Dallas, Texas +4 locations
Conditions: Head and Neck Cancer
Register for Updates
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00294762
Completed
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: University of Texas M.D. Anderson Cancer Center, Houston, Texas
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
NCT00038168
Completed
Phase I: The goal of this clinical research study is to find the highest dose of estramustine phosphate administered intravenously in combination with a fixed dose of Taxol (paclitaxel) that can be given safely to participants with prostate cancer who have failed to further benefit from hormone treatment. Phase II: The goal of this clinical research study is to find out if the combination of the drugs estramustine phosphate and paclitaxel will shrink or control prostate cancer that has not resp... Read More
Gender:
MALE
Ages:
All
Trial Updated:
07/31/2012
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
NCT00002837
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose combination chemotherapy and peripheral stem cell transplantation in treating patients with recurrent or metastatic breast cancer.
Gender:
ALL
Ages:
Between 15 years and 60 years
Trial Updated:
07/27/2012
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement
NCT00508326
Completed
The goal of this clinical research study is find the highest tolerated dose of paclitaxel that can be given directly into the liver of patients with advanced cancer involving the liver. Researchers also want to collect descriptive information on any effects the drug may have on tumor tissue.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
07/27/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer
Register for Updates
Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
NCT00512096
Completed
Primary Objective: -To evaluate the feasibility and efficacy of multimodality treatment (neoadjuvant chemotherapy prior to extirpative surgery) for clinical stage TXN2-3M0 squamous cell carcinoma of the penis.
Gender:
MALE
Ages:
14 years and above
Trial Updated:
07/27/2012
Locations: U.T.M.D. Anderson Cancer Center, Houston, Texas
Conditions: Penile Cancer
Register for Updates
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
NCT00003084
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/27/2012
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer
NCT00006081
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 and paclitaxel in treating patients who have unresectable locally advanced or metastatic stomach cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/27/2012
Locations: CCOP - M.D. Anderson Research Base, Houston, Texas +1 locations
Conditions: Esophageal Cancer, Gastric Cancer
Register for Updates
S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00002969
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with paclitaxel in treating patients with stage IIIB or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +6 locations
Conditions: Lung Cancer
Register for Updates
S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00003158
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy and chemotherapy consisting of carboplatin, etoposide and paclitaxel in treating patients with newly diagnosed stage III non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2012
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +6 locations
Conditions: Lung Cancer
Register for Updates